CSOP Biotech(03174.HK) up 2.89%, AstraZeneca $2bn Akeso partner deal

NewTimeSpace News: Hong Kong innovative drug shares opened higher this morning. As of 09:57 HKT on September 29, 2026, CSOP Hang Seng Biotech ETF (03174.HK) traded at HK$3.914, up 2.89%, with turnover of HK$2,176,400, volume of 564,000 units and a turnover rate of 0.22%.

The ETF is managed by CSOP Asset Management Limited and tracks the Hang Seng Biotech Index, which covers biotech companies listed in Hong Kong. As of 09:57 HKT on September 29, 2026, it had assets of HK$972 million, a net asset value of HK$3.800 per unit and a board lot of 100 units.

Reported by Zhitong Finance, Summit Therapeutics, the overseas partner of Akeso (09926.HK), announced that AstraZeneca will make a US$2 billion strategic equity investment in it and will lead clinical studies of Akeso's first-in-class PD-1/VEGF bispecific antibody ivonescimab combined with AstraZeneca's CLDN18.2 antibody-drug conjugate in multiple gastrointestinal tumours. 

CITIC Securities noted in a research report that China's innovative drugs have seen rapid domestic uptake in 2026, with leading drugmakers posting fast revenue growth on new products and biopharma companies gradually returning to profit; overseas pipelines are entering Phase III and registration read-outs, and with several major international academic conferences approaching, many pipelines are entering a dense period of data catalysts.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.